Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer
Galectin Therapeutics (NASDAQ: GALT) has appointed Dr. Khurram Jamil as Chief Medical Officer, effective immediately. Dr. Jamil, who joined the company in March 2024 as VP of Clinical Development and Medical Director, brings over 20 years of experience in hepatology and drug development. He will lead the management of the NAVIGATE clinical trial for belapectin, a potential treatment for MASH cirrhosis.
The company expects interim top-line data from the Phase 2b portion of the NAVIGATE trial in December 2024. This trial is evaluating belapectin's efficacy in preventing esophageal varices in patients with cirrhosis due to MASH. The study has randomized 357 patients across 14 countries on five continents.
Galectin Therapeutics (NASDAQ: GALT) ha nominato Dr. Khurram Jamil come Direttore Medico, con effetto immediato. Il Dr. Jamil, che è entrato nell'azienda a marzo 2024 come VP dello Sviluppo Clinico e Direttore Medico, porta con sé oltre 20 anni di esperienza in epatologia e nello sviluppo di farmaci. Guiderà la gestione del trial clinico NAVIGATE per il belapectin, un potenziale trattamento per la cirrosi MASH.
L'azienda prevede di ottenere dati preliminari nella fase 2b del trial NAVIGATE a dicembre 2024. Questo trial sta valutando l'efficacia del belapectin nella prevenzione delle varici esofagee in pazienti con cirrosi causata da MASH. Lo studio ha randomizzato 357 pazienti in 14 paesi su cinque continenti.
Galectin Therapeutics (NASDAQ: GALT) ha nombrado al Dr. Khurram Jamil como Director Médico, con efecto inmediato. El Dr. Jamil, que se unió a la compañía en marzo de 2024 como VP de Desarrollo Clínico y Director Médico, aporta más de 20 años de experiencia en hepatología y desarrollo de fármacos. Dirigirá la gestión del ensayo clínico NAVIGATE para el belapectin, un posible tratamiento para la cirrosis MASH.
La empresa espera datos preliminares de la fase 2b del ensayo NAVIGATE en diciembre de 2024. Este ensayo está evaluando la eficacia del belapectin en la prevención de varices esofágicas en pacientes con cirrosis debido a MASH. El estudio ha randomizado a 357 pacientes en 14 países de cinco continentes.
갈렉틴 치료제 (NASDAQ: GALT)는 Khurram Jamil 박사를 최고 의학 책임자로 즉시 임명했습니다. Jamil 박사는 2024년 3월 임상 개발 부사장 겸 의학 이사로 회사에 합류했으며, 간병학 및 약물 개발 분야에서 20년 이상의 경험을 보유하고 있습니다. 그는 NAVIGATE 임상 시험의 관리를 이끌어갈 것이며, 이는 MASH 간경변에 대한 잠재적 치료제인 belapectin에 대한 것입니다.
회사는 2024년 12월에 NAVIGATE 시험의 2b 단계에서 임시 주요 데이터를 발표할 것으로 예상하고 있습니다. 이 시험은 MASH로 인한 간경변 환자에서 식도 정맥류 예방을 위한 belapectin의 효능을 평가하고 있으며, 5개 대륙의 14개국에서 357명의 환자가 무작위 배정되었습니다.
Galectin Therapeutics (NASDAQ: GALT) a nommé Dr. Khurram Jamil en tant que Directeur Médical, avec effet immédiat. Le Dr. Jamil, qui a rejoint l'entreprise en mars 2024 en tant que VP Développement Clinique et Directeur Médical, apporte plus de 20 ans d'expérience en hépatologie et développement de médicaments. Il dirigera la gestion de l'
L'entreprise s'attend à des données préliminaires de la phase 2b de l'essai NAVIGATE en décembre 2024. Cet essai évalue l'efficacité du belapectin dans la prévention des varices œsophagiennes chez les patients atteints de cirrhose due à MASH. L'étude a randomisé 357 patients dans 14 pays sur cinq continents.
Galectin Therapeutics (NASDAQ: GALT) hat Dr. Khurram Jamil zum Chief Medical Officer ernannt, mit sofortiger Wirkung. Dr. Jamil, der im März 2024 als VP für klinische Entwicklung und medizinischer Direktor in das Unternehmen eingetreten ist, bringt mehr als 20 Jahre Erfahrung in der Hepatologie und Arzneimittelentwicklung mit. Er wird die Leitung der NAVIGATE-Studie für Belapectin übernehmen, eine potenzielle Behandlung für MASH-Zirrhose.
Das Unternehmen erwartet im Dezember 2024 interimistische Daten aus dem Phase-2b-Teil der NAVIGATE-Studie. Diese Studie bewertet die Wirksamkeit von Belapectin bei der Prävention von Ösophagusvarizen bei Patienten mit Zirrhose aufgrund von MASH. In der Studie wurden 357 Patienten in 14 Ländern auf fünf Kontinenten randomisiert.
- Appointment of experienced Dr. Khurram Jamil as Chief Medical Officer
- NAVIGATE clinical trial for belapectin progressing as planned
- Interim top-line data readout expected in December 2024
- Large-scale trial with 357 patients across 14 countries
- Previous Chief Medical Officer, Dr. Pol Boudes, is no longer with the company
NORCROSS, Ga., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of Khurram Jamil, M.D., an accomplished senior executive with expertise in liver disease to Chief Medical Officer effective immediately.
Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said “We are very excited to elevate Dr. Jamil to Chief Medical Officer. After joining us in March 2024 as Vice President Clinical Development and Medical Director, Khurram has quickly integrated himself into our team and has led the management of our NAVIGATE clinical trial of belapectin. Khurram is well known in the hepatology community and has over 20 years of experience. After completing his general surgery residency at Seton Hall University, Khurram had several roles with increasing responsibility in biotechnology and pharmaceutical companies where he designed and led many clinical trials, several of which resulted in new drug approvals in the United States and other countries around the world. We have confidence in Khurram’s leadership of NAVIGATE and look forward to the Interim Analysis results in December 2024.”
Dr. Khurram Jamil stated, “I am honored that Joel and the Board of Directors have selected me to become the Chief Medical Officer and lead the belapectin program. I believe my experience and passion for developing new therapeutics is a great match for the needs of the Company at this time. MASH cirrhosis is a very large and growing unmet medical need, and belapectin has shown significant promise that it could be an important therapeutic for these patients. I am committed to getting the results of the Interim Analysis of NAVIGATE in December 2024.”
Dr. Jamil will succeed Dr. Pol Boudes, who is no longer employed by the Company. Mr. Lewis continued, “We thank Dr. Boudes for his service and wish him well in his future endeavors.”
Belapectin Program
Belapectin is a complex carbohydrate drug that targets galectin-3, a critical protein in the pathogenesis of MASH and fibrosis.
MASH Cirrhosis
- The NAVIGATE Phase 2b/3 trial (NCT04365868) evaluating the efficacy and safety of belapectin for the prevention of esophageal varices in patients with cirrhosis due to MASH is progressing as planned. With in 357 patients randomized across 14 countries on five continents Interim top-line data readout from the Phase 2b portion of the trial is anticipated in December 2024.
About Galectin Therapeutics
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. Liver cirrhosis is one of the most pressing medical needs and a significant drug development opportunity. Additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as “may,” “estimate,” “could,” “expect,” “look forward,” “believe,” “hope” and others. They are based on management’s current expectations and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the statements. These statements include those regarding the hope that Galectin’s development program for belapectin will lead to the first therapy for the treatment of MASH, formerly known as NASH, with cirrhosis and those regarding the hope that our lead compounds will be successful in cancer immunotherapy and in other therapeutic indications. Factors that could cause actual performance to differ materially from those discussed in the forward-looking statements include, among others, that trial endpoints required by the FDA may not be achieved; Galectin may not be successful in developing effective treatments and/or obtaining the requisite approvals for the use of belapectin or any of its other drugs in development; the Company may not be successful in scaling up manufacturing and meeting requirements related to chemistry, manufacturing and control matters; the Company’s current clinical trial and any future clinical studies may not produce positive results in a timely fashion, if at all, and could require larger and longer trials, which would be time consuming and costly; plans regarding development, approval and marketing of any of Galectin’s drugs are subject to change at any time based on the changing needs of the Company as determined by management and regulatory agencies; regardless of the results of any of its development programs, Galectin may be unsuccessful in developing partnerships with other companies or raising additional capital that would allow it to further develop and/or fund any studies or trials. Galectin has incurred operating losses since inception, and its ability to successfully develop and market drugs may be impacted by its ability to manage costs and finance continuing operations. For a discussion of additional factors impacting Galectin’s business, see the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, and subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause its views to change, management disclaims any obligation to update forward-looking statements.
Company Contact:
Jack Callicutt, Chief Financial Officer
(678) 620-3186
ir@galectintherapeutics.com
Investors Relations Contacts:
Kevin Gardner
kgardner@lifesciadvisors.com
Chris Calabrese
ccalabrese@lifesciadvisors.com
Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics’ galectin-3 inhibitor belapectin.
FAQ
What is the latest management change at Galectin Therapeutics (GALT)?
When is Galectin Therapeutics (GALT) expecting interim results for the NAVIGATE trial?
What is the NAVIGATE trial by Galectin Therapeutics (GALT) studying?
How many patients are enrolled in Galectin Therapeutics' (GALT) NAVIGATE trial?
